Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for prevention of doxorubicin-induced cardiotoxicity in breast cancer
IRCT20231014059713N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in breast cancer and drug-induced cardiomyopathy comparing Empagliflozin arm with Placebo arm (2 arms). Primary endpoint: Cardiotoxicity incidence. Started Nov 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
breast cancerdrug-induced cardiomyopathy
Beyond the preview
Go deeper on IRCT20231014059713N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231014059713N1.